Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node.
van Pul KM, Vuylsteke RJCLM, van de Ven R, Te Velde EA, Rutgers EJT, van den Tol PM, Stockmann HBAC, de Gruijl TD. van Pul KM, et al. Among authors: vuylsteke rjclm. J Immunother Cancer. 2019 May 22;7(1):133. doi: 10.1186/s40425-019-0605-1. J Immunother Cancer. 2019. PMID: 31118093 Free PMC article.
Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma.
Vuylsteke RJ, Molenkamp BG, Gietema HA, van Leeuwen PA, Wijnands PG, Vos W, van Diest PJ, Scheper RJ, Meijer S, de Gruijl TD. Vuylsteke RJ, et al. Cancer Res. 2004 Nov 15;64(22):8456-60. doi: 10.1158/0008-5472.CAN-03-3251. Cancer Res. 2004. PMID: 15548718 Clinical Trial.
Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic Treg reduction and effector T cell activation.
van Pul KM, Notohardjo JCL, Fransen MF, Koster BD, Stam AGM, Chondronasiou D, Lougheed SM, Bakker J, Kandiah V, van den Tol MP, Jooss K, Vuylsteke RJCLM, van den Eertwegh AJM, de Gruijl TD. van Pul KM, et al. Among authors: vuylsteke rjclm. Sci Immunol. 2022 Jul 15;7(73):eabn8097. doi: 10.1126/sciimmunol.abn8097. Epub 2022 Jul 15. Sci Immunol. 2022. PMID: 35857579 Clinical Trial.
Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials.
Koster BD, van den Hout MFCM, Sluijter BJR, Molenkamp BG, Vuylsteke RJCLM, Baars A, van Leeuwen PAM, Scheper RJ, Petrousjka van den Tol M, van den Eertwegh AJM, de Gruijl TD. Koster BD, et al. Among authors: vuylsteke rjclm. Clin Cancer Res. 2017 Oct 1;23(19):5679-5686. doi: 10.1158/1078-0432.CCR-17-0944. Clin Cancer Res. 2017. PMID: 28972083 Clinical Trial.
In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma.
Koster BD, de Jong TD, van den Hout MFCM, Sluijter BJR, Vuylsteke RJCLM, Molenkamp BG, Vosslamber S, van den Tol MP, van den Eertwegh AJM, de Gruijl TD. Koster BD, et al. Among authors: vuylsteke rjclm. Oncoimmunology. 2019 Dec 26;9(1):1708066. doi: 10.1080/2162402X.2019.1708066. eCollection 2020. Oncoimmunology. 2019. PMID: 32002303 Free PMC article.
34 results